Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
What's the purpose of the trial?
The goal of this clinical trial is to learn more about the safety and effectiveness of investigational drug Mezigdomide given in combination with approved treatments Bortezomib and Dexamethasone. Researchers will compare this investigational combination against standard of care treatments Pomalidomide, Bortezomib and Dexamethasone to learn more about how Mezigdomide works in relapsed or refractory multiple myeloma.
There are 23 centers participating in this trial. Enter a location below to find the closet center.
Learn more about the experimental treatments being evaluated in this clinical trial.
- Mezigdomide (CC-92480)
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!